Merck Viresolve® Pro Virus Removal Membrane Cartridge

Overview

The Merck Viresolve® Pro Virus Removal Membrane Cartridge is a high-performance, single-use, low-protein-binding polyethersulfone (PES) membrane device engineered for robust and scalable parvovirus clearance in biopharmaceutical downstream processing. It operates on the principle of size-based exclusion combined with optimized surface chemistry and pore structure geometry to achieve consistent log reduction values (LRV) ≥ 4.0 for model parvoviruses—including Minute Virus of Mice (MVM)—under validated process conditions. Designed for integration into commercial-scale purification trains, the Viresolve® Pro cartridge delivers predictable performance across diverse monoclonal antibody (mAb), Fc-fusion protein, and viral vector feedstreams, supporting regulatory filings under ICH Q5A(R2) and aligned with FDA and EMA guidance on virus clearance validation.

Key Features

• High-capacity, asymmetric PES membrane with controlled pore morphology for simultaneous high flow rate and high virus retention
• Validated LRV ≥ 4.0 for MVM at process-relevant loadings (up to 100 L/m²) and fluxes (≥ 50 LMH)
• Low nonspecific protein binding (< 5 µg/cm² for IgG), minimizing product loss and maintaining yield integrity
• Scalable from lab-scale (10 cm²) to production-scale (up to 2.5 m² active area per cartridge)
• Pre-sterilized, gamma-irradiated, and supplied in ready-to-use, fully assembled housings compliant with ISO 11664
• Compatible with standard sanitary clamp (DIN 11851) and tri-clamp connections for seamless integration into stainless steel or single-use skids

Sample Compatibility & Compliance

Viresolve® Pro is qualified for use with clarified harvests from mammalian cell culture (CHO, SP2/0, HEK293), including feeds containing up to 10 g/L host cell proteins (HCP) and 5% (v/v) DNA. It demonstrates stability across pH 4.5–8.5 and conductivity ranges of 1–15 mS/cm. The system complies with USP endotoxin limits (< 0.25 EU/mL effluent), meets ISO 13485 manufacturing requirements, and supports full traceability per FDA 21 CFR Part 11 through electronic batch records. All lot-specific validation data—including extractables profiling per USP , leachables assessment, and biocompatibility per ISO 10993-5—are provided in the Certificate of Analysis and Regulatory Support File (RSF).

Software & Data Management

While Viresolve® Pro is a passive filtration device requiring no embedded electronics, its implementation is supported by Merck’s Process Validation Toolkit—comprising Design of Experiments (DoE) templates, failure mode and effects analysis (FMEA) worksheets, and process characterization protocols aligned with ICH Q8(R2) and Q9. Raw data from integrity testing (forward flow, water intrusion), pressure monitoring, and flux decay profiling can be integrated into commercial MES platforms (e.g., Siemens Opcenter, Rockwell FactoryTalk) via CSV export or OPC UA interface. Audit trails, user access controls, and electronic signatures are maintained when deployed within validated LIMS or ELN environments compliant with ALCOA+ principles.

Applications

• Final polishing step for monoclonal antibodies and bispecifics prior to sterile filtration
• Virus clearance in AAV and lentiviral vector purification workflows
• Downstream processing of recombinant enzymes and therapeutic proteins expressed in mammalian systems
• Platform process development where rapid scalability and regulatory precedent are critical
• Backup or orthogonal virus removal step in multi-tiered clearance strategies

FAQ

What virus types is Viresolve® Pro validated against?
Viresolve® Pro is primarily validated for parvoviruses—especially MVM—as the worst-case model for small, non-enveloped viruses. Additional studies support clearance of Reo-3 and PPV; enveloped virus removal (e.g., VSV, MuLV) is typically higher but not the primary design target.
Can Viresolve® Pro be used with high-titer AAV preparations?
Yes—extensive testing shows stable flux and LRV retention with AAV serotypes (AAV2, AAV5, AAV8) at titers up to 1 × 10¹⁴ vg/mL when operated within specified transmembrane pressure (≤ 3.5 bar) and temperature (4–25°C) windows.
Is pre-filtering mandatory?
Use of Viresolve® Pro Shield or Viresolve® ProShield H pre-filters is strongly recommended to extend main cartridge lifetime and maintain consistent LRV, especially with feeds containing > 100 ppm particles > 0.5 µm or > 50 ppm aggregates.
How is integrity testing performed?
Forward flow test (FF) is the primary method per ASTM F838-22; bubble point (BP) and water intrusion (WI) tests are also qualified alternatives depending on process fluid composition and facility SOPs.
Does Merck provide regulatory documentation for submissions?
Yes—the Regulatory Support File includes full validation reports, extractables/leachables data, biocompatibility summaries, and precedents from approved marketing applications (BLA, MAA) to support global regulatory filings.